5 research outputs found
Image_1_Systematic evaluation of urinary formic acid as a new potential biomarker for Alzheimer’s disease.PDF
IntroductionThe accumulation of endogenous formaldehyde is considered a pathogenic factor in Alzheimer’s disease (AD). The purpose of this study was to investigate the relationship between urinary formic acid and plasma biomarkers in AD.Materials and methodsFive hundred and seventy-four participants were divided into five groups according to their diagnosis: 71 with normal cognitive (NC), 101 with subjective cognitive decline (SCD), 131 with cognitive impairment without mild cognitive impairment (CINM), 158 with mild cognitive impairment (MCI), and 113 with AD.ResultsWith the progression of the disease, urinary formic acid levels showed an overall upward trend. Urinary formic acid was significantly correlated with Mini-Mental State Examination (MMSE) scores, the Chinese version of Addenbrooke’s Cognitive Examination III (ACE-III) scores, and Montreal Cognitive Assessment-Basic (MoCA-B) time. The areas under the receiver operating characteristic curves (AUC) of urinary formic acid in distinguishing NC from AD was 0.797, which was similar to that of plasma neurofilament light chain (NfL; AUC = 0.768) and better than other plasma biomarkers (Aβ40, Aβ42, Aβ42/Aβ40, T-tau, P-tau181, and P-tau181/T-tau). We also found that using urinary formic acid and formaldehyde levels could improve the accuracy of using plasma biomarkers to determine AD disease stage.DiscussionOur study revealed the possibility of urinary formic acid as a potential novel biomarker for the early diagnosis of AD.</p
Data_Sheet_1_Dcf1 Deficiency Attenuates the Role of Activated Microglia During Neuroinflammation.pdf
<p>Microglia serve as the principal immune cells and play crucial roles in the central nervous system, responding to neuroinflammation via migration and the execution of phagocytosis. Dendritic cell-derived factor 1 (Dcf1) is known to play an important role in neural stem cell differentiation, glioma apoptosis, dendritic spine formation, and Alzheimer’s disease (AD), nevertheless, the involvement of the Dcf1 gene in the brain immune response has not yet been reported. In the present paper, the RNA-sequencing and function enrichment analysis suggested that the majority of the down-regulated genes in Dcf1<sup>-/-</sup> (Dcf1-KO) mice are immune-related. In vivo experiments showed that Dcf1 deletion produced profound effects on microglial function, increased the expression of microglial activation markers, such as ionized calcium binding adaptor molecule 1 (Iba1), Cluster of Differentiation 68 (CD68) and translocator protein (TSPO), as well as certain proinflammatory cytokines (Cxcl1, Ccl7, and IL17D), but decreased the migratory and phagocytic abilities of microglial cells, and reduced the expression levels of some other proinflammatory cytokines (Cox-2, IL-1β, IL-6, TNF-α, and Csf1) in the mouse hippocampus. Furthermore, in vitro experiments revealed that in the absence of lipopolysaccharide (LPS), the majority of microglia were ramified and existed in a resting state, with only approximately 10% of cells exhibiting an amoeboid-like morphology, indicative of an activated state. LPS treatment dramatically increased the ratio of activated to resting cells, and Dcf1 downregulation further increased this ratio. These data indicated that Dcf1 deletion mediates neuroinflammation and induces dysfunction of activated microglia, preventing migration and the execution of phagocytosis. These findings support further investigation into the biological mechanisms underlying microglia-related neuroinflammatory diseases, and the role of Dcf1 in the immune response.</p
sj-pdf-1-jcb-10.1177_0271678X231153730 - Supplemental material for In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer’s disease
Supplemental material, sj-pdf-1-jcb-10.1177_0271678X231153730 for In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer’s disease by Junfang Zhang, Jie Wang, Xiaomeng Xu, Zhiwen You, Qi Huang, Yiyun Huang, Qihao Guo, Yihui Guan, Jun Zhao, Jun Liu, Wei Xu, Yulei Deng, Fang Xie and Binyin Li in Journal of Cerebral Blood Flow & Metabolism</p
Discovery of 1,2,3-Triazole Derivatives for Multimodality PET/CT/Cryoimaging of Myelination in the Central Nervous System
Myelin pathology is present in many
neurological conditions such
as multiple sclerosis (MS) and traumatic spinal cord injury (SCI).
To facilitate development of novel therapies aimed at myelin repair,
we set out to develop imaging agents that permit direct quantification
of myelination in vivo. In this work, we designed and synthesized
a series of fluorescent fluorinated myelin imaging agents that can
be used for in vivo positron emission tomography (PET) imaging combined
with subsequent post-mortem fluorescent cryoimaging. Structure–activity
relationship (SAR) studies of the newly developed myelin imaging agents
led us to identify a lead compound (TAFDAS, <b>21</b>) that
readily enters the brain and spinal cord and selectively binds to
myelin. By conducting sequential PET and 3D cryoimaging in an SCI
rat model, we demonstrated for the first time that PET and cryoimaging
can be combined as a novel technique to image the spinal cord with
high sensitivity and spatial resolution
Discovery of 1,2,3-Triazole Derivatives for Multimodality PET/CT/Cryoimaging of Myelination in the Central Nervous System
Myelin pathology is present in many
neurological conditions such
as multiple sclerosis (MS) and traumatic spinal cord injury (SCI).
To facilitate development of novel therapies aimed at myelin repair,
we set out to develop imaging agents that permit direct quantification
of myelination in vivo. In this work, we designed and synthesized
a series of fluorescent fluorinated myelin imaging agents that can
be used for in vivo positron emission tomography (PET) imaging combined
with subsequent post-mortem fluorescent cryoimaging. Structure–activity
relationship (SAR) studies of the newly developed myelin imaging agents
led us to identify a lead compound (TAFDAS, <b>21</b>) that
readily enters the brain and spinal cord and selectively binds to
myelin. By conducting sequential PET and 3D cryoimaging in an SCI
rat model, we demonstrated for the first time that PET and cryoimaging
can be combined as a novel technique to image the spinal cord with
high sensitivity and spatial resolution